Accomplishments in 2011

Zoo WalkThe Sickle Cell Cure Foundation, Inc. (SCCF) has had a very successful and productive year. The highlights are listed below.

  1. As a direct result of having our laboratory and office within the Presbyterian Health Foundation (PHF) Research Park, SCCF has formed collaborations that enhance our ability to achieve our most important goals. Emblematic of these interactions are the CDAs (Confidential Disclosure Agreements) SCCF has exchanged with five companies in 2011. These discussions and interactions are aimed at achieving commercialization of our patented technologies for treating human diseases, with malaria and sickle cell disease being on a global scale.
  2. Foremost among our collaborations is the one formed with Dr. Sunil Joshi, PhD, DVM, who is also a Gates GCE Phase I grantee. Dr. Joshi has been a key to the success of our safety and efficacy trials in mice, the primary aim of our Gates-funded work this year.
  3. A second key collaboration is with a very successful analytical company in the PHF Research Park, who have allowed SCCF to borrow an HPLC apparatus (a $60,000 instrument) we desperately needed to do our hemoglobin analyses on both human and mouse samples.
  4. Our most important collaboration with been with Haus Bioceuticals (Adam Payne, Managing Partner) which has been key to being able to flesh out our Gates Phase II grant proposal, which includes the first human clinical trials for our key therapeutic candidate for both malaria and sickle cell disease (SCD). The first trials are planned for mid-2013, in either India or Brazil, two scientifically capable countries where both malaria and SCD are endemic.
  5. For applications of our therapeutics to important diseases other than SCD & malaria, such as diabetes, cancer, cardiovascular diseases, and neurodegenerative diseases including Alzheimer’s and Parkinson’s, we formed a spin-off for-profit company called EpimedX, LLC, incorporated 22 August 2011. The main mission of this company will be to license our patented technologies for these other disease applications.
  6. SCCF made a total of 8 scientific presentations at four international conferences during 2011, which helped establish contacts in Thailand, Nigeria, and Ghana, for Phase II and III clinical trials in ca. 2014.
  7. Our most far-reaching collaboration came late in 2011 with a third party who is the world’s largest supplier of our main therapeutic candidate. This company has already demonstrated that the naturally-occurring compound has a favorable safety profile – a key for international distribution of a treatment that may be therapeutically effective towards malaria and SCD.


  1. Thank you for the update! Great progress!

  2. i have been living with sickle cell for a month to eighteen years now. it has not been easy at all.please work on the cure more intently. i will gladly participate in your projects. thank you and keep up the good work

  3. olarewaju yahya daud says

    I pray that Almighty God makes your effort fruitful in finding a permanent cure to sickle cell. I could not imagine thr pain and trouble that sickle cell patient undergo not until I had to breakup with a woman I love cos of fear of giving birth to children with anaemia

Speak Your Mind